Your browser doesn't support javascript.
loading
Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol.
Zhang, Yiyi; Dron, Jacqueline S; Bellows, Brandon K; Khera, Amit V; Liu, Junxiu; Balte, Pallavi P; Oelsner, Elizabeth C; Amr, Sami Samir; Lebo, Matthew S; Nagy, Anna; Peloso, Gina M; Natarajan, Pradeep; Rotter, Jerome I; Willer, Cristen; Boerwinkle, Eric; Ballantyne, Christie M; Lutsey, Pamela L; Fornage, Myriam; Lloyd-Jones, Donald M; Hou, Lifang; Psaty, Bruce M; Bis, Joshua C; Floyd, James S; Vasan, Ramachandran S; Heard-Costa, Nancy L; Carson, April P; Hall, Michael E; Rich, Stephen S; Guo, Xiuqing; Kazi, Dhruv S; de Ferranti, Sarah D; Moran, Andrew E.
Affiliation
  • Zhang Y; Division of General Medicine, Columbia University, New York, New York.
  • Dron JS; Cardiovascular Disease Initiative, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge.
  • Bellows BK; Center for Genomic Medicine, Massachusetts General Hospital, Boston.
  • Khera AV; Division of General Medicine, Columbia University, New York, New York.
  • Liu J; Cardiovascular Disease Initiative, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge.
  • Balte PP; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Oelsner EC; Division of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Amr SS; Department of Population Health Science and Policy, Icahn School of Medicine, Mount Sinai, New York, New York.
  • Lebo MS; Division of General Medicine, Columbia University, New York, New York.
  • Nagy A; Division of General Medicine, Columbia University, New York, New York.
  • Peloso GM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Natarajan P; Laboratory for Molecular Medicine, Personalized Medicine, Mass General Brigham, Cambridge, Massachusetts.
  • Rotter JI; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Willer C; Laboratory for Molecular Medicine, Personalized Medicine, Mass General Brigham, Cambridge, Massachusetts.
  • Boerwinkle E; Laboratory for Molecular Medicine, Personalized Medicine, Mass General Brigham, Cambridge, Massachusetts.
  • Ballantyne CM; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
  • Lutsey PL; Cardiovascular Disease Initiative, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge.
  • Fornage M; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Lloyd-Jones DM; Department of Medicine, Massachusetts General Hospital, Boston.
  • Hou L; The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.
  • Psaty BM; Department of Internal Medicine, University of Michigan, Ann Arbor.
  • Bis JC; Department of Human Genetics, University of Michigan, Ann Arbor.
  • Floyd JS; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor.
  • Vasan RS; Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston.
  • Heard-Costa NL; Department of Medicine, Baylor College of Medicine, Houston, Texas.
  • Carson AP; Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis.
  • Hall ME; The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston.
  • Rich SS; Northwestern University, Chicago, Illinois.
  • Guo X; Northwestern University, Chicago, Illinois.
  • Kazi DS; Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle.
  • de Ferranti SD; Department of Epidemiology, University of Washington, Seattle.
  • Moran AE; Department of Health Systems and Population Health, University of Washington, Seattle.
JAMA Cardiol ; 9(3): 263-271, 2024 Mar 01.
Article in En | MEDLINE | ID: mdl-38294787
ABSTRACT
Importance Familial hypercholesterolemia (FH) is a genetic disorder that often results in severely high low-density lipoprotein cholesterol (LDL-C) and high risk of premature coronary heart disease (CHD). However, the impact of FH variants on CHD risk among individuals with moderately elevated LDL-C is not well quantified.

Objective:

To assess CHD risk associated with FH variants among individuals with moderately (130-189 mg/dL) and severely (≥190 mg/dL) elevated LDL-C and to quantify excess CHD deaths attributable to FH variants in US adults. Design, Setting, and

Participants:

A total of 21 426 individuals without preexisting CHD from 6 US cohort studies (Atherosclerosis Risk in Communities study, Coronary Artery Risk Development in Young Adults study, Cardiovascular Health Study, Framingham Heart Study Offspring cohort, Jackson Heart Study, and Multi-Ethnic Study of Atherosclerosis) were included, 63 of whom had an FH variant. Data were collected from 1971 to 2018, and the median (IQR) follow-up was 18 (13-28) years. Data were analyzed from March to May 2023. Exposures LDL-C, cumulative past LDL-C, FH variant status. Main Outcomes and

Measures:

Cox proportional hazards models estimated associations between FH variants and incident CHD. The Cardiovascular Disease Policy Model projected excess CHD deaths associated with FH variants in US adults.

Results:

Of the 21 426 individuals without preexisting CHD (mean [SD] age 52.1 [15.5] years; 12 041 [56.2%] female), an FH variant was found in 22 individuals with moderately elevated LDL-C (0.3%) and in 33 individuals with severely elevated LDL-C (2.5%). The adjusted hazard ratios for incident CHD comparing those with and without FH variants were 2.9 (95% CI, 1.4-6.0) and 2.6 (95% CI, 1.4-4.9) among individuals with moderately and severely elevated LDL-C, respectively. The association between FH variants and CHD was slightly attenuated when further adjusting for baseline LDL-C level, whereas the association was no longer statistically significant after adjusting for cumulative past LDL-C exposure. Among US adults 20 years and older with no history of CHD and LDL-C 130 mg/dL or higher, more than 417 000 carry an FH variant and were projected to experience more than 12 000 excess CHD deaths in those with moderately elevated LDL-C and 15 000 in those with severely elevated LDL-C compared with individuals without an FH variant. Conclusions and Relevance In this pooled cohort study, the presence of FH variants was associated with a 2-fold higher CHD risk, even when LDL-C was only moderately elevated. The increased CHD risk appeared to be largely explained by the higher cumulative LDL-C exposure in individuals with an FH variant compared to those without. Further research is needed to assess the value of adding genetic testing to traditional phenotypic FH screening.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Coronary Artery Disease / Cardiovascular Diseases / Atherosclerosis / Hypercholesterolemia / Hyperlipoproteinemia Type II Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: JAMA Cardiol Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Coronary Artery Disease / Cardiovascular Diseases / Atherosclerosis / Hypercholesterolemia / Hyperlipoproteinemia Type II Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: JAMA Cardiol Year: 2024 Document type: Article Country of publication: